Toxoplasma Seroprevalence Rates
Author(s) -
Aaron E. Glatt
Publication year - 2003
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/374672
Subject(s) - medicine , seroprevalence , virology , immunology , antibody , serology
Correspondence Toxoplasma Seroprevalence Rates Sir—I read with interest the fine paper by Falusi et al. [1] in the 1 December 2002 issue of Clinical Infectious Diseases. This large study confirms previously published data on Toxoplasma seroprevalence rates. The authors state that such data come from small, predominantly male cohorts in which the range of prevalence is 3%–22%. The authors neglect to cite our earlier publication [2], which demonstrates a se-roprevalence rate of nearly 23% in a co-hort of 319 HIV-seropositive patients (22.6% Toxoplasma seroprevalence among the 93 women in this cohort). Our sero-prevalence findings and ethnicity (e.g., birth country) data from 10 years ago are corroborated by Falusi et al. [1]. However, unlike their study, ours did not demonstrate a higher seroprevalence rate among patients with lower CD4 cell counts. Indeed , although our results were not statistically significant, our 138 patients with cell counts of !200 CD4 cells/mL had a lower Toxoplasma seroprevalence rate than did our patients with cell counts of у200 CD4 cells/mL.alence and predictors of Toxoplasma seroposi-tivity in women with and at risk for human immunodeficiency virus infection. Sir—We appreciate Dr. Glatt's interest [1] in our study of Toxoplasma seroprevalence in HIV-infected women in the United States [2]. We regret the omission of the study by Glatt et al. [3] from our references but failed to find the article in the Medline search performed during our literature review process. It is interesting to note that the 22.6% Toxoplasma seroprev-alence rate reported in their cohort of 319 patients (which included 93 women) was just slightly greater than the range we cited in our study (3%–22%). As stated in our study discussion, we were unable to explain the higher Toxo-plasma seroprevalence rate among patients with CD4 cell counts of 200–500 cells/ mm 3. It is important to note that, although there was a trend towards higher sero-prevalence rates among patients with lower CD4 cell counts, this was statistically significant only for patients with CD4 cell counts of 200–500 cells/mm 3 (on univar-iate and multivariate analysis) and not for patients with CD4 cell counts of !200 cells/mm 3. This association with CD4 cell count stratum could not be explained by country of birth or by age, because these variables were controlled for in the multi-variate analysis. Consistent with the observations of Glatt et al. [3], we found that, among HIV-infected women in the United States, country of birth (i.e., …
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom